Q2 revenue up 196% year-over-year. HBM sold out through 2026. Wall Street is racing to raise targets....
Domestic
Gene editing, non-opioid pain, and a CF monopoly. CRSP and VRTX are the names everyone is searching...
MU has surged over 200% YTD, Wolfe Research just raised its target to $1,250, and Q3 fiscal...
Record revenue, raised guidance, a CFO exit — and the stock drops. The setup is more interesting...
AMZN moved Prime Day to June — earlier, longer, and with more at stake than any prior...
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn't Anthropic —...
AAPL slid while NVDA notched a stealth victory — and the divergence between their options flows tells...
AVGO drops 12%+ on a quarter that beat EPS — here's the real story behind the selloff
The sector that lagged tech for two years is quietly building one of the best fundamental setups...
The numbers from Q1 2026 are too big to talk around — and the market still hasn't...
